Abstract
Background: Bupropion is an effective smoking cessation therapy but its use in the UK has been limited by concerns that it may increase the risk of sudden death.
Methods: Data for all patients prescribed bupropion within The Health Improvement Network (a computerised general practice database) were extracted and the self-controlled case-series method was used to estimate the relative incidence of death during the first 28 days of treatment. The incidence of seizures, a recognised adverse effect of bupropion, was also investigated during this period.
Results: A total of 9329 individuals had been prescribed bupropion (mean age 44 years, 48% male). The total person-time after the first prescription for bupropion was 17 586 years, and during this time 121 people died. Two people died within the first 28 days of treatment, which was less than expected in comparison with the remaining observation period by an incidence ratio of 0.50 (95% confidence interval (CI) 0.12 to 2.05). Twenty eight people were recorded as having a total of 45 seizures (23 before starting bupropion, two in the first 28 days of treatment, and 20 at a later point). The relative incidence of seizures during the first 28 days of treatment was 3.62 (95% CI 0.87 to 15.09), equivalent to one additional seizure per 6219 first time bupropion users.
Conclusions: Bupropion use is probably associated with an increased risk of seizures, but no evidence was found to suggest that the drug is associated with an increased risk of sudden death.
Full Text
The Full Text of this article is available as a PDF (58.8 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Anthonisen N. R., Connett J. E., Kiley J. P., Altose M. D., Bailey W. C., Buist A. S., Conway W. A., Jr, Enright P. L., Kanner R. E., O'Hara P. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994 Nov 16;272(19):1497–1505. [PubMed] [Google Scholar]
- Boshier Andrew, Wilton Lynda V., Shakir Saad A. W. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol. 2003 Nov 13;59(10):767–773. doi: 10.1007/s00228-003-0693-0. [DOI] [PubMed] [Google Scholar]
- Bourke Alison, Dattani Hassy, Robinson Michael. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care. 2004;12(3):171–177. doi: 10.14236/jhi.v12i3.124. [DOI] [PubMed] [Google Scholar]
- Dunner D. L., Zisook S., Billow A. A., Batey S. R., Johnston J. A., Ascher J. A. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry. 1998 Jul;59(7):366–373. doi: 10.4088/jcp.v59n0705. [DOI] [PubMed] [Google Scholar]
- Farrington C. P., Nash J., Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol. 1996 Jun 1;143(11):1165–1173. doi: 10.1093/oxfordjournals.aje.a008695. [DOI] [PubMed] [Google Scholar]
- Farrington P., Pugh S., Colville A., Flower A., Nash J., Morgan-Capner P., Rush M., Miller E. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet. 1995 Mar 4;345(8949):567–569. doi: 10.1016/s0140-6736(95)90471-9. [DOI] [PubMed] [Google Scholar]
- Hubbard Richard, Farrington Paddy, Smith Chris, Smeeth Liam, Tattersfield Anne. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol. 2003 Jul 1;158(1):77–84. doi: 10.1093/aje/kwg114. [DOI] [PubMed] [Google Scholar]
- Johnston J. A., Lineberry C. G., Ascher J. A., Davidson J., Khayrallah M. A., Feighner J. P., Stark P. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry. 1991 Nov;52(11):450–456. [PubMed] [Google Scholar]
- Pisani Francesco, Oteri Giancarla, Costa Cinzia, Di Raimondo Giorgio, Di Perri Raoul. Effects of psychotropic drugs on seizure threshold. Drug Saf. 2002;25(2):91–110. doi: 10.2165/00002018-200225020-00004. [DOI] [PubMed] [Google Scholar]
- Settle E. C., Jr Bupropion sustained release: side effect profile. J Clin Psychiatry. 1998;59 (Suppl 4):32–36. [PubMed] [Google Scholar]
- Walley T., Mantgani A. The UK General Practice Research Database. Lancet. 1997 Oct 11;350(9084):1097–1099. doi: 10.1016/S0140-6736(97)04248-7. [DOI] [PubMed] [Google Scholar]
- West R., McNeill A., Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax. 2000 Dec;55(12):987–999. doi: 10.1136/thorax.55.12.987. [DOI] [PMC free article] [PubMed] [Google Scholar]